GSK prioritises innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is the company's R&D focus on the science of ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged.

Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

PFG Investments LLC lifted its position in GSK plc (NYSE:GSK – Free Report) by 8.5% in the 3rd quarter, Holdings Channel.com ...

The companies have plans to evaluate IDE275 as a monotherapy and combined with immunotherapy in MSI-high solid tumors.